海利Hile品牌怎么样 申请店铺

成立于1981年，上海市著名商标，上海名牌，上市公司，兽用生物制品及动物重大疫情防治药品生产基地，集专业化兽用生物制品研发/生产/销售/服务于一体的高新技术企业。

上海海利生物技术股份有限公司(SH:603718)（以下简称“公司”）是一家集研发、生产、销售、服务于一体的专业化兽用生物制品生产企业。公司成立于1981年，其前身为上海松江生物药品厂。公司产品线齐全，产品结构完善，拥有家禽、家畜、宠物三大类共计44个产品，2015年5月公司成功登陆国内A股主板市场，目前总股本为64400万股。

近年来，公司也不断积极开拓终端市场，促进新产品研发进度、新工艺转化落实，加快新疫苗生产设施的建设速度，提高公司核心竞争能力，并与全球企业不断开展深度合作。公司与口蹄疫疫苗生产商之一的阿根廷Biogénse BagóS.A.公司（以下简称“BB公司”）合资设立的控股子公司杨凌金海生物技术有限公司将采用BB公司稳定的全悬浮、高纯化生产工艺技术进行口蹄疫疫苗的生产，其工艺规模化技术水平位居全球行业前列。与此同时，公司积极开展对外投资，积极落实“动保+人保”的双轮驱动布局，目前主要投资公司有上海序康医疗科技有限公司、上海裕隆生物科技有限公司。2017年公司发起设立了上海润瓴投资合伙企业（有限合伙），将为公司在“人保”领域的拓展提供更多的渠道和储备项目，有利于公司在更广阔平台上做强做大。

Founded in 1981, Shanghai famous brand, listed company, animal biological products and animal major epidemic prevention and control drug production base, a high-tech enterprise integrating specialized animal biological products research and development / production / sales / services. Shanghai Haili Biotechnology Co., Ltd. (SH: 603718) (hereinafter referred to as "the company") is a specialized animal biological products manufacturer integrating research and development, production, sales and service. The company was founded in 1981, its predecessor is Shanghai Songjiang biological medicine factory. The company has a complete product line, complete product structure, and 44 products in three categories: poultry, livestock and pets. In May 2015, the company successfully landed in the domestic A-share main board market, with a total share capital of 644 million shares. In recent years, the company has also been actively exploring the terminal market, promoting the progress of new product research and development, the implementation of new process transformation, accelerating the construction of new vaccine production facilities, improving the company's core competitiveness, and continuously carrying out in-depth cooperation with global enterprises. Yangling Jinhai Biotechnology Co., Ltd., a holding subsidiary jointly established by the company and Biog é nsebag ó S.A. of Argentina (hereinafter referred to as "BB company"), one of the manufacturers of FMD vaccine, will adopt the stable full suspension and high purification production technology of BB company to produce FMD vaccine, and its technology scale technology level ranks the top in the global industry. At the same time, the company actively carried out foreign investment and actively implemented the two wheel drive layout of "dynamic insurance + human insurance". At present, the main investment companies are Shanghai Xukang Medical Technology Co., Ltd. and Shanghai Yulong Biotechnology Co., Ltd. In 2017, the company initiated the establishment of Shanghai runling investment partnership (limited partnership), which will provide more channels and reserve projects for the company's expansion in the field of "human resources insurance", and help the company to become stronger and bigger on a broader platform.

本文链接： https://brand.waitui.com/7a4d8515e.html 联系电话：021-60890888,60890812